Collexis Holdings, Inc. Acquires SyynX Solutions GmbH, Expands Application Portfolio

SyynX Solutions GmbHCollexis Holdings, Inc. (OTCBB: CLXS) has acquired its long-time development partner, SyynX Solutions, a privately-held software company based in Cologne, Germany. SyynX Solutions will remain as a subsidiary of Collexis Holdings – with the amendment "a Collexis company", and will take care of existing customers and drive Collexis' business in Europe. The SyynX management team will be part of the Collexis Holdings management team.

The joint history of both companies:
SyynX and Collexis were founded at the same time in 1999 as offspring of an EU funded research project. SyynX started then to develop parts of the fingerprint technology for Collexis. In less than ten years Collexis has become the market leader of knowledge applications especially for the scientific context. In 2005 Collexis moved its global headquarters to Columbia, South Carolina and introduced the SyynX applications to the American market. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). The applications developed by SyynX are based on the patented Collexis fingerprint technology, i.e. the Knowledge or Protein Dashboard, the search platform Mediator and the Social Networking platform for the Life Sciences with more than 1M of pre-populated expert profiles. The later was recently jointly developed with Collexis and will be launched at the beginning of 2008.

"After working together with the Collexis team for several years, the SyynX team is more than excited about bringing the two companies together," says Christian Herzog, MD, CEO of SyynX Solutions. "The Collexis Fingerprint core technology, combined with the applications built by SyynX, will provide a great advantage to existing customers, as well as future ones."

Bill Kirkland, CEO of Collexis. "The SyynX software component is an ideal strategic complement to our existing capabilities as the market leader in high-definition search and discovery solutions. Our comprehensive offerings address a growing market trend, as scientists are increasingly recognizing the essential role that informatics, database and workflow solutions play in more effectively managing research programs and driving higher productivity. We believe that the acquisition of SyynX will position Collexis as a global leader in providing these solutions and our value proposition to clients will be stronger as a result."

Related news article:

About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of High Definition Search and Discovery software since 1999, is headquartered in Columbia, South Carolina (USA) with two subsidiaries; Collexis Inc. in Columbia, South Carolina, USA and Collexis, B.V. in Geldermalsen, The Netherlands. Collexis proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis shares of common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, please visit www.collexis.com.

About SyynX Solutions GmbH
SyynX Solutions GmbH is a German software company which focuses on text mining based applications for the areas of life science and health care. Collexis and SyynX are already co-operating closely since almost ten years on the technical and commercial level. The SyynX applications based on the Collexis fingerprint technology are used by customers like universities, pharmaceutical and biotech companies around the world. The text mining applications like the SyynX Knowledge Dashboard helps the user to analyze large text corpora without applying standard search approaches and provides him automatically with expert profiles, trends and knowledge discovery routines. For more information please visit www.syynx.de.

Most Popular Now

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Unusual type of antibody shows ultrapotent activit…

An unusual type of antibody that even at miniscule levels neutralizes the Zika virus and renders the virus infection undetectable in preclinical models has been identifie...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...